Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
NCT00492401 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55
Last updated 2016-06-27
Summary
This phase II trial is studying how well decitabine works in treating patients with previously untreated acute myeloid leukemia. Drugs used in chemotherapy, such as decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing
Conditions
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Adult Acute Myeloid Leukemia With Del(5q)
- Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Secondary Acute Myeloid Leukemia
- Untreated Adult Acute Myeloid Leukemia
Interventions
- DRUG
-
decitabine
Given IV
- OTHER
-
laboratory biomarker analysis
Correlative studies
- OTHER
-
pharmacological study
Correlative studies
- OTHER
-
high performance liquid chromatography
Correlative studies
- GENETIC
-
microarray analysis
Correlative studies
- GENETIC
-
RNA analysis
Correlative studies
- OTHER
-
mass spectrometry
Correlative studies
- GENETIC
-
DNA methylation analysis
Correlative studies
- OTHER
-
matrix-assisted laser desorption/ionization time of flight mass spectrometry
Correlative studies
Sponsors & Collaborators
-
National Cancer Institute (NCI)
lead NIH
Principal Investigators
-
William Blum · Ohio State University
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2007-05-31
- Primary Completion
- 2010-12-31
- Completion
- 2014-10-31
Countries
- United States
Study Locations
More Related Trials
-
Omacetaxine and Decitabine in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS)
NCT02141477 ·Status: TERMINATED ·Phase: PHASE1
-
Decitabine and Valproic Acid in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT00079378 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Decitabine for Treatment of Older Patients With Acute Myeloid Leukemia (AML)
NCT00358644 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients
NCT02109744 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Decitabine in Treating Patients With Myelodysplastic Syndrome
NCT00003361 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
NCT00042016 ·Status: COMPLETED ·Phase: PHASE2
-
Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
NCT00475150 ·Status: COMPLETED ·Phase: PHASE2
-
Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia
NCT00703300 ·Status: COMPLETED ·Phase: PHASE1
-
CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase
NCT00084916 ·Status: COMPLETED ·Phase: PHASE2
-
Decitabine in Patients With Chronic Myelomonocytic Leukemia (CMML)
NCT01098084 ·Status: COMPLETED ·Phase: PHASE2
-
Decitabine, Cytarabine, GCSF for Refractory AML/MDS
NCT00740181 ·Status: TERMINATED ·Phase: PHASE2
-
Genomic Predictors of Decitabine Response in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes
NCT01687400 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy of Decitabine in Clearance of MRD
NCT03021395 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia
NCT01130662 ·Status: COMPLETED ·Phase: PHASE1
-
Randomized Study of Decitabine in Maintenance Therapy of Acute Myeloid Leukemia (AML)
NCT00398983 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects
NCT01177540 ·Status: TERMINATED ·Phase: PHASE2
-
A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction Chemotherapy Compared With Immediate Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects
NCT00943553 ·Status: WITHDRAWN ·Phase: PHASE2
-
Pharmacokinetic Trial of Decitabine (Dacogen) Administered as a 3-hour Infusion to Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
NCT01378416 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Decitabine in Combination With Escalating Doses of Rapamycin in Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT00861874 ·Status: COMPLETED ·Phase: PHASE1
-
Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
NCT00042003 ·Status: COMPLETED ·Phase: PHASE2
-
Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia
NCT03063203 ·Status: TERMINATED ·Phase: PHASE2
-
Decitabine, Vorinostat, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
NCT01130506 ·Status: COMPLETED ·Phase: PHASE1
-
Decitabine Followed by Clofarabine, Idarubicin, and Cytarabine in Acute Leukemia
NCT01794702 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Pevonedistat and Decitabine in Treating Patients With High Risk Acute Myeloid Leukemia
NCT03009240 ·Status: COMPLETED ·Phase: PHASE1
-
DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
NCT01834248 ·Status: COMPLETED ·Phase: PHASE1